BIOMAT Database Logo BIOMAT Database Logo

HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics. 1993

A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Department of Medicinal Chemistry, Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.

A series of glycopeptidemimetics based on the hydroxyethylene Phe-Phe isostere have been synthesized and evaluated for their ability to inhibit the enzyme HIV-1 protease. Incorporation of carbohydrate moieties at the P'2-position and elimination of P'3 amino acid in our lead compound 1, provided inhibitors with only nanomolar potencies (400-800 nM). However, incorporation of a carbohydrate moiety at the P'3-position with branched chain amino acid at the P'2-position, resulted in inhibitors with subnanomolar potencies. Within this series, compound 21 was the most potent inhibitor (IC50 value 0.17 nM). This compound has also shown to block the spread of HIV-1 in T-lymphoid cells at an inhibitor concentration of 200 nM.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
May 2003, Journal of medicinal chemistry,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.
July 2005, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
September 2019, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.
June 2019, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
May 2015, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies.
March 2023, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
June 2008, ChemMedChem,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as C2-Symmetric HIV-1 Protease Inhibitors and Docking Study.
January 2019, Biological & pharmaceutical bulletin,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
February 2006, Bioorganic & medicinal chemistry letters,
A K Ghosh, and S P McKee, and W M Sanders, and P L Darke, and J A Zugay, and E A Emini, and W A Schleif, and J C Quintero, and J R Huff, and P S Anderson
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
February 2019, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!